Promoting global health: utilizing WHO to integrate public health, innovation and intellectual property

被引：7
作者：
Mackey, Tim K. [1 ,2 ]
Liang, Bryan A. [1 ,3 ,4 ]
机构：
[1] Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA USA
[2] Univ Calif San Diego, Joint Doctoral Program Global Hlth, San Diego State Univ, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Sch Med, San Diego Ctr Patient Safety, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Sch Med, Dept Anesthesiol, San Diego, CA 92103 USA
来源：
DRUG DISCOVERY TODAY | 2012年 / 17卷 / 23-24期
关键词：
PATENT-LAW; MEDICINES; TRIPS; DISEASES; ACCESS;
D O I：
10.1016/j.drudis.2012.06.012
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The appropriate role of innovation and intellectual property (IP) in global public health is a controversial issue. Discussion is one-sided, with potential benefits advocated by industry in stark contrast to condemnation by certain civil society players. WHO's Public Health, Innovation and Intellectual Property Department (PHI) was established to address healthcare resource need for developing countries, assess impact of innovation and IP on access to medicines, explore innovative funding mechanisms for R&D and provide evidence-based policy-making recommendations in response to the changing global health landscape. Importantly, PHI could represent a potential forum to bridge shared, yet often diverse, interests and opportunities between various public and private stakeholders, a crucial issue for ensuring the future viability of WHO.
引用
收藏
页码：1254 / 1257
页数：4
相关论文
共 34 条
[11]   Meeting the Demand for Results and Accountability: A Call for Action on Health Data from Eight Global Health Agencies [J].
Chan, Margaret ;
Kazatchkine, Michel ;
Lob-Levyt, Julian ;
Obaid, Thoraya ;
Schweizer, Julian ;
Sidibe, Michel ;
Veneman, Ann ;
Yamada, Tadataka .
PLOS MEDICINE, 2010, 7 (01)
[12]  
Consultative Expert Working Group, CONS EXP WORK GROUP
[13]   Key factors in the rising cost of new drug discovery and development [J].
Dickson, M ;
Gagnon, JP .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :417-429
[14]   The WHO Pandemic Influenza Preparedness Framework: A Milestone in Global Governance for Health [J].
Fidler, David P. ;
Gostin, Lawrence O. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (02) :200-201
[15]  
International Federation of Pharmaceutical Manufacturers & Associations, RES DEV
[16]   TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? [J].
Kerry, Vanessa Bradford ;
Lee, Kelley .
GLOBALIZATION AND HEALTH, 2007, 3
[17]   The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks [J].
Mackey, Tim K. ;
Liang, Bryan A. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (11) :4571-4579
[18]   Choosing the right incentive strategy for research and development in neglected diseases [J].
Maurer, Stephen M. .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2006, 84 (05) :376-381
[19]  
Medicines Patent Pool, 2019, WHO WE AR
[20]  
Milstien J, 2006, B WORLD HEALTH ORGAN, V84, P360, DOI 10.2471/BLT.05.028431
1234